Piramal sells its cartilage repair product
14 January 2016 | News | By BioSpectrum Bureau
Piramal sells its cartilage repair product
BST-CarGel is a first-line cartilage repair product used along with microfracture and other bone marrow
Piramal Enterprises announces the sale of BST-CarGel from Piramal Healthcare (Canada) Limited, based in Montreal, Canada to Smith and Nephew, the global medical technology business.
BST-CarGel is a first-line cartilage repair product used along with microfracture and other bone marrow stimulation techniques for the initial treatment of most sizes of focal cartilage tears.
Through this transaction, an affiliate of Smith and Nephew will acquire ownership of all product and intellectual property assets related to BST-CarGel.
The transaction does not have a material impact on the financials of Piramal.
